Thus, development of anti-FGFR4 CAR-T cells not only broadens the spectrum of CAR-T cell therapy targets for HCC but also compensates for the shortcomings of FGFR4 inhibitors. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.